Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Efavirenz

FDA-approved product (capsule, oral), marketed as Efavirenz, Sustiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Efavirenz
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Efavirenz in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Efavirenz with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

    NCT01985399 · start 2013-12

    Registered record
    Registry ID
    NCT01985399
    Conditions
    HIV; AIDS
    Interventions
    Neuropsychological testing
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS
    InterventionNeuropsychological testing
    PhaseNot recorded
    Registry statusCompleted

  • Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction

    NCT01410058 · start 2013-01

    Registered record
    Registry ID
    NCT01410058
    Conditions
    HIV
    Interventions
    Moringa oleifera; Efavirenz 600mg; Nevirapine 200Mg Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-09
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionMoringa oleifera; Efavirenz 600mg; Nevirapine 200Mg Oral Tablet
    PhaseNot recorded
    Registry statusCompleted

  • Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

    NCT01694017 · start 2012-11

    Registered record
    Registry ID
    NCT01694017
    Conditions
    HIV
    Interventions
    Tenofovir; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir; Zidovudine
    PhasePhase 4
    Registry statusCompleted

  • Antiretroviral Therapy and Extreme Weight

    NCT01805427 · start 2012-09

    Registered record
    Registry ID
    NCT01805427
    Conditions
    HIV Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

    NCT01513941 · start 2012-04

    Registered record
    Registry ID
    NCT01513941
    Conditions
    Chronic Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated-Interferon-alfa-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-06
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated-Interferon-alfa-2a
    PhasePhase 3
    Registry statusCompleted

  • A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    NCT01467479 · start 2011-12

    Registered record
    Registry ID
    NCT01467479
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2014-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    PhasePhase 3
    Registry statusTerminated

  • Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01495702 · start 2011-12

    Registered record
    Registry ID
    NCT01495702
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    NNRTI; FTC/TDF; Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-12
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionNNRTI; FTC/TDF; Stribild
    PhasePhase 3
    Registry statusCompleted

  • A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

    NCT01472380 · start 2011-11

    Registered record
    Registry ID
    NCT01472380
    Conditions
    Healthy
    Interventions
    efavirenz; fenofibric acid 105 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2012-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionefavirenz; fenofibric acid 105 mg
    PhasePhase 1
    Registry statusCompleted

  • The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

    NCT01451333 · start 2011-09

    Registered record
    Registry ID
    NCT01451333
    Conditions
    HIV Infection
    Interventions
    Efavirenz; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionEfavirenz; Efavirenz
    PhasePhase 3
    Registry statusCompleted

  • BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

    NCT01641016 · start 2011-04

    Registered record
    Registry ID
    NCT01641016
    Conditions
    HIV
    Interventions
    efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2011-04
    Completion
    2016-06
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventionefavirenz
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Influence of Nevirapine on HCV Viral Load

    NCT01277627 · start 2011-01

    Registered record
    Registry ID
    NCT01277627
    Conditions
    HCV Infection.; HCV Viral Load.
    Interventions
    Nevirapine; efavirenz, protease inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Infection.; HCV Viral Load.
    InterventionNevirapine; efavirenz, protease inhibitors
    PhaseNot applicable
    Registry statusUnknown

  • Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

    NCT01194856 · start 2010-10

    Registered record
    Registry ID
    NCT01194856
    Conditions
    HIV Infection; Mitochondrial Dysfunction
    Interventions
    Atazanavir/ritonavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-10
    Completion
    2011-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Mitochondrial Dysfunction
    InterventionAtazanavir/ritonavir; Efavirenz
    PhasePhase 4
    Registry statusTerminated

  • GSK1349572 Drug Interaction Study With Efavirenz

    NCT01098526 · start 2010-03-16

    Registered record
    Registry ID
    NCT01098526
    Conditions
    Infections, Human Immunodeficiency Virus and Herpesviridae
    Interventions
    GSK1349572; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03-16
    Completion
    2010-05-26
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Human Immunodeficiency Virus and Herpesviridae
    InterventionGSK1349572; Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

    NCT00978068 · start 2009-09

    Registered record
    Registry ID
    NCT00978068
    Conditions
    Malaria; HIV Infections
    Interventions
    Lopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; HIV Infections
    InterventionLopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    PhasePhase 3
    Registry statusCompleted

  • A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

    NCT00870363 · start 2009-04

    Registered record
    Registry ID
    NCT00870363
    Conditions
    HIV Infections
    Interventions
    maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-04
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionmaraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
    PhasePhase 4
    Registry statusCompleted